In8Bio (INAB) Free Cash Flow (2020 - 2026)
In8Bio (INAB) posted Free Cash Flow of -$4.9 million for Q1 2026, down 130.48% sequentially from -$2.1 million in Q4 2025, and down 57.91% YoY from -$11.7 million in Q1 2025.
In8Bio (INAB) Free Cash Flow (2020 - 2026) Analysis & Trends
In8Bio has reported Free Cash Flow for 7 years, with the latest figure at -$4.9 million in Q1 2026.
- Quarterly Free Cash Flow fell 57.91% year-over-year to -$4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.5 million (up 24.79% YoY) and the FY2025 annual result came in at -$12.7 million, up 47.4% from the prior year.
- Free Cash Flow fell to -$4.9 million in Q1 2026 per INAB's latest filing, from -$2.1 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$2.1 million in Q4 2025 and troughed at -$11.6 million in Q4 2022.
- A 5-year average of -$5.5 million and a median of -$5.3 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow tumbled 432.63% in 2022, then surged 60.9% in 2025.
- Over 5 years, Free Cash Flow stood at -$11.6 million in 2022, then soared by 54.66% to -$5.3 million in 2023, then rose by 24.28% to -$4.0 million in 2024, then surged by 46.24% to -$2.1 million in 2025, then sank by 130.48% to -$4.9 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$4.9 million, -$2.1 million, and -$3.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - | -4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.00 Mn |
| Jun 30, 2026 | -4.00 Mn |
| Mar 31, 2026 | -4.93 Mn |
| Mar 31, 2026 | -4.93 Mn |
| Dec 31, 2025 | -2.14 Mn |
| Dec 31, 2025 | -2.14 Mn |
| Sep 30, 2025 | -3.52 Mn |
| Sep 30, 2025 | -3.52 Mn |
| Jun 30, 2025 | -3.93 Mn |
| Jun 30, 2025 | -3.93 Mn |
| Mar 31, 2025 | -3.12 Mn |
| Mar 31, 2025 | -3.12 Mn |
| Dec 31, 2024 | -3.98 Mn |
| Dec 31, 2024 | -3.98 Mn |
| Sep 30, 2024 | -6.12 Mn |
| Sep 30, 2024 | -6.12 Mn |
| Jun 30, 2024 | -6.09 Mn |
| Jun 30, 2024 | -6.09 Mn |
| Mar 31, 2024 | -7.98 Mn |
| Mar 31, 2024 | -7.98 Mn |